Physician

Aliakbar Rashid Dadla, M.D.

According to 2025 Medicare claims, Aliakbar Dadla, M.D. (NPI: 1134474976) practices medical oncology in the Olympia-Lacey-Tumwater, WA market, with the plurality of this provider's patient population coming from Thurston, WA. This provider's primary affiliated billing organization is NORTHWEST MEDICAL SPECIALTIES PLLC (NPI: 1548261308; TIN: 911867315) and primary practice location at 98502-8703. Dadla is affiliated with the PSW ACO (ACO ID: A5323), participating under the MSSP model.

Dadla's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 550 traditional Medicare patients, billed 134,286 HCPCS/CPT codes, and received $1,972,247 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,120 prescription claims across 207 beneficiaries totaling $2,537,330 in drug costs, led by Pomalyst (Pomalidomide). 2020 DME data shows 256 claims. Open Payments data shows 60 records totaling $1,112. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $44,403 to $1,972,247. Similarly, Part D prescription costs have risen steadily, from $18,346 to $2,537,330. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	219	742	$44,403
2019	357	1,882	$104,727
2020	414	1,944	$109,339
2021	399	1,127	$78,766
2022	194	670	$64,922
2023	515	99,790	$1,408,650
2024	550	134,286	$1,972,247

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	51	130	$18,346
2016	77	247	$128,602
2017	71	256	$303,531
2018	95	291	$352,384
2019	149	484	$200,818
2020	184	849	$1,393,075
2021	186	754	$1,047,747
2022	180	1,080	$1,229,014
2023	217	868	$1,695,518
2024	207	1,120	$2,537,330

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	154	$5,603
2020	N/R	256	$18,975
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	99	99	$164
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	157	256	$129
96413	Administration of chemotherapy into vein, 1 hour or less	89	273	$101
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	262	549	$91
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	124	233	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	31	868	$755,201
Calquence	Acalabrutinib Maleate	46	1,380	$597,033
Lenalidomide	Lenalidomide	21	588	$261,831
Brukinsa	Zanubrutinib	22	840	$232,775
Imbruvica	Ibrutinib	15	444	$188,424

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	60	$1,112	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Aliakbar Rashid Dadla, M.D.?

Tedicare shows public-source Medicare data for Aliakbar Rashid Dadla, M.D. (NPI 1134474976), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Aliakbar Rashid Dadla, M.D. have ACO affiliation data?

Aliakbar Rashid Dadla, M.D. is shown with ACO affiliation data for PSW ACO (MSSP, ACO ID A5323).

What billing organization is linked to Aliakbar Rashid Dadla, M.D.?

Aliakbar Rashid Dadla, M.D. is linked to NORTHWEST MEDICAL SPECIALTIES PLLC (billing NPI 1548261308) in the available physician profile data.

Does Aliakbar Rashid Dadla, M.D. have Open Payments data?

Aliakbar Rashid Dadla, M.D. has 60 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.